ODN 21595 is a Guanine-ModifiedTLR7andTLR9inhibitor. ODN 21595 inhibits the release of IFN-α andIL-6with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE)^[1].

ODN 21595 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs^[1].
ODN 21595 (0.01, 0.1, 1, 10 μM; 48 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human PBMCs^[1].
ODN 21595 (0.1, 1, 10 μM; 24 h) inhibits the secretion of IL-6 in CpG-ODN 2006 (100 nM) and imiquimod (5 μg/ml) stimulated human B-cells^[1].
ODN 21595 (1, 10 μM; 48 h) displays a lower stimulatory activity and reduces significantly the CpG-ODN 2006 (100 nM) or imiquimod (5 μg/ml)-induced expression of CD86 or HLA-DR in CD20⁺B-cells^[1].

1964506-28-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.